• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Clin Transl Neurol . Long COVID-19: Objectifying most self-reported neurological symptoms

tetano

Editor, Senior Moderator
Ann Clin Transl Neurol


. 2022 Jan 20.
doi: 10.1002/acn3.51496. Online ahead of print.
Long COVID-19: Objectifying most self-reported neurological symptoms


Julia Bungenberg[SUP] 1 2 [/SUP], Karen Humkamp[SUP] 1 [/SUP], Christian Hohenfeld[SUP] 1 2 [/SUP], Marcus Immanuel Rust[SUP] 1 [/SUP], Ummehan Ermis[SUP] 1 [/SUP], Michael Dreher[SUP] 3 [/SUP], Niels-Ulrik Korbinian Hartmann[SUP] 4 [/SUP], Gernot Marx[SUP] 5 [/SUP], Ferdinand Binkofski[SUP] 6 [/SUP], Carsten Finke[SUP] 7 [/SUP], Jörg B Schulz[SUP] 1 2 [/SUP], Ana Sofia Costa[SUP] 1 2 [/SUP], Kathrin Reetz[SUP] 1 2 [/SUP]



Affiliations

Abstract

Objectives: We aimed to objectify and compare persisting self-reported symptoms in initially hospitalized and non-hospitalized patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by applying clinical standardized measures.
Methods: We conducted a cross-sectional study of adult patients with confirmed SARS-CoV-2 infection including medical history, neurological examination, blood markers, neuropsychological testing, patient-reported outcome measures (PROMs), and brain magnetic resonance imaging (MRI).
Results: Fifty patients with persisting symptoms for at least 4 weeks were included and classified by initial hospitalization status. Median time from SARS-CoV-2 detection to investigation was 29.3 weeks (range 3.3-57.9). Although individual cognitive performance was generally within the normative range in both groups, mostly mild deficits were found in attention, executive functions, and memory. Hospitalized patients performed worse in global cognition, logical reasoning, and processes of verbal memory. In both groups, fatigue severity was associated with reduced performance in attention and psychomotor speed tasks (r[SUB]s[/SUB] = -0.40, p < 0.05) and reduced quality of life (EQ5D, r[SUB]s[/SUB] = 0.57, p < 0.001) and with more persisting symptoms (median 3 vs. 6, p < 0.01). PROMs identified fatigue, reduced sleep quality, and increased anxiety and depression in both groups but more pronounced in non-hospitalized patients. Brain MRI revealed microbleeds exclusively in hospitalized patients (n = 5).
Interpretation: Regardless of initial COVID-19 severity, an individuals' mental and physical health can be severely impaired in the long-term limitedly objectified by clinical standard diagnostic with abnormalities primarily found in hospitalized patients. This needs to be considered when planning rehabilitation therapies and should give rise to new biomarker research.
 
Back
Top Bottom